Welcome to our dedicated page for Ashland news (Ticker: $ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ashland's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ashland's position in the market.
Ashland Inc. (ASH) board of directors has approved a quarterly dividend of $0.405 per share, marking a five percent increase from the prior quarter. The dividend will be paid on June 15, 2024, to stockholders on record as of June 1, 2024. As of April 30, 2024, there were 50,128,349 shares of Ashland common stock outstanding.
Turnspire Capital Partners has announced the acquisition of the nutraceuticals business of Ashland Inc. The acquisition includes Ashland Nutraceuticals, a leading provider of nutrition ingredients and custom formulation services for the nutrition market. Ashland Nutraceuticals has approximately 500 employees across four production facilities in the US and Mexico. The transaction is expected to be completed in the third quarter of 2024.
Ashland Inc. (NYSE: ASH) has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners The transaction is set to close in the third quarter of 2024. Ashland's nutraceuticals business offers active ingredients and formulation aids to nutritional product companies, alongside custom formulation and contract manufacturing services. The deal highlights the business's strong portfolio and capabilities.
Ashland Inc. (NYSE: ASH) reported financial results for the second quarter of fiscal year 2024, with sales at $575 million, down five percent from the prior-year quarter. Net income reached $120 million, or $2.39 per diluted share. Adjusted EBITDA was $126 million, and cash flows from operating activities were $54 million. The company's outlook for the third quarter and full-year fiscal 2024 shows an optimistic perspective on the demand normalization in key segments like Personal Care and Specialty Additives.
